- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02865018
Neuromyelitis Optica (NMO) & Cetirizine
An Open Label, add-on Trial of Cetirizine for Patients With Neuromyelitis Optica
Neuromyelitis optica (NMO) is an autoimmune disease that affects the central nervous system. Patients have relapses (also known as attacks) which are often quite severe and leave them with significant disability. Without treatment, within 5 years 50% of NMO patients are blind in one or both eyes or require walking assistance (cane, walker or wheelchair).
NMO has only been relatively recently described and is fairly rare. Most NMO patients' immune systems produce abnormal antibodies against aquaporin-4 (AQP4), which is found in certain cells in the central nervous system. When these AQP4 antibodies bind to AQP4, they trigger a cascade of events involving the immune system which eventually leads to damage to the nervous system. This ultimately leads to disability, some of which is permanent.
Until now, treatments for NMO have been mostly focused on decreasing production of this AQP4 antibody. However, recent experiments in animal models of NMO have shown the importance of what happens inside the central nervous system after the antibody binds to the nervous system cell. Specifically, researchers have noted the importance of a specific cell type, eosinophils, in causing damage in NMO lesions. In a recent study, researchers showed they could prevent damage from NMO by blocking eosinophils using cetirizine, which is a popular over-the-counter allergy medicine.
Cetirizine is already known to be safe and well-tolerated in the general population. In this study, the researchers plan to add cetirizine on to patients' current NMO treatment. The researchers aim to show that it is safe, well-tolerated, and that with cetirizine, NMO patients have less relapses and therefore less disability over the course of the year following initiation of treatment. The researchers also plan to study how cetirizine changes the immunological profile in NMO patients by examining blood and cerebrospinal fluid.
Study Overview
Detailed Description
The researchers hypothesize that cetirizine, an allergy medication that acts as an eosinophil-stabilizer, will decrease the relapse rate when added to current standard therapy in patients with neuromyelitis optica.
Medication compliance will be assessed by the research coordinator at each visit through discussion with the patient and pill counting.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years to 85
- Meet criteria for the diagnosis of neuromyelitis optica as outlined by Wingerchuk et al in 2006. Alternatively patients may be included if they have had an episode of myelitis or optic neuritis in combination with a positive NMO IgG antibody, as positive antibody with a first episode is highly associated with future relapse.
- Disease duration of at least 6 months
- Stable, without any NMO relapses, for the 3 months prior to the baseline assessment visit
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
Exclusion Criteria:
- Current therapy with daily cetirizine or another daily antihistamine for any indication
- Known hypersensitivity to cetirizine, hydroxyzine, or any component of the formulation
- Change in NMO disease-modifying therapy in the 3 months prior to baseline assessment
- Pregnancy or planning pregnancy during the study period
- Severe renal or hepatic impairment
- Inability to complete the study protocol for any reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cetirizine
10mg oral each day
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Annualized Relapse Rate Before Cetirizine
Time Frame: Baseline and 1 year
|
Relapses defined as "patient-reported symptoms or objectively observed signs typical of an acute inflammatory demyelinating event in the CNS, with duration of at least 24 hours, in the absence of fever or infection."
The on study ARR was calculated as the number of relapses during the study divided by the length of time in the study.
|
Baseline and 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Epworth Sleepiness Scale
Time Frame: Baseline and 1 year
|
Sedation as measured by Epworth Sleepiness Scale.
The test is a list of eight situations in which you rate your tendency to become sleepy on a scale of 0, no chance of dozing, to 3, high chance of dozing.
Total score 0 to 24 from unlikelihood of abnormally sleep to excessively sleepy.
|
Baseline and 1 year
|
Expanded Disability Status Scale (EDSS)
Time Frame: Baseline and 1 year
|
Disability as measured by Expanded Disability Status Scale (EDSS).
The EDSS provides a total score on a scale from 0 to 10, from normal function to lessening function with higher score, 10, being death due to MS.
|
Baseline and 1 year
|
Eotaxin Plasma Levels
Time Frame: 6 months
|
Eotaxin - an eosinophil-specific chemoattractant in the blood.
Immunological measures related to eosinophil activity.
Eotaxin plasma levels.
|
6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ilana Katz Sand, MD, Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Eye Diseases
- Optic Nerve Diseases
- Cranial Nerve Diseases
- Myelitis, Transverse
- Optic Neuritis
- Neuromyelitis Optica
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Histamine H1 Antagonists, Non-Sedating
- Cetirizine
Other Study ID Numbers
- 13-1513
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromyelitis Optica
-
Jagannadha R AvasaralaTerminatedMultiple Sclerosis | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder Attack | Neuromyelitis Optica Spectrum Disorder Relapse | Neuromyelitis Optica Spectrum Disorder ProgressionUnited States
-
MedImmune LLCCompletedNeuromyelitis Optica and Neuromyelitis Optica Spectrum DisordersUnited States, Czechia, Thailand, Germany, Korea, Republic of, Israel, New Zealand, Spain, Taiwan, Japan, Turkey, Hungary, Bulgaria, Mexico, Russian Federation, Colombia, Peru, Poland, Estonia, South Africa, Canada, Australia, Hong... and more
-
Feng JinzhouNot yet recruitingNeuromyelitis Optica Spectrum Disorders
-
BiocadRecruitingNeuromyelitis Optica Spectrum DisordersRussian Federation
-
First Affiliated Hospital of Fujian Medical UniversityThird Affiliated Hospital, Sun Yat-Sen University; MyBiotech Co. Ltd, ChinaCompletedNeuromyelitis Optica Spectrum DisordersChina
-
Tianjin Medical University General HospitalCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum DisordersChina
-
Fu-Dong ShiCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum Disorders | Devic's DiseaseChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityZhongshan Ophthalmic Center, Sun Yat-sen University; Southern Medical University...UnknownMycophenolate Mofetil | Neuromyelitis Optica Spectrum Disorders | Efficacy and Safety
-
Reistone Biopharma Company LimitedCompletedNeuromyelitis Optica Spectrum DisordersChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityNanfang Hospital of Southern Medical University; Second Affiliated Hospital... and other collaboratorsUnknownNeuromyelitis Optica Spectrum DisordersChina
Clinical Trials on cetirizine
-
Novartis PharmaceuticalsCompletedAllergic RhinitisCanada
-
UCB PharmaCompleted
-
Johnson & Johnson Consumer Inc., McNeil Consumer...Completed
-
ShionogiCompletedSeasonal Allergic Rhinitis
-
Biolipox ABCompletedAllergic RhinitisSweden
-
GlaxoSmithKlineCompletedRhinitis, Allergic, Perennial
-
GlaxoSmithKlineCompletedRhinitis, Allergic, Perennial
-
Ranbaxy Laboratories LimitedOhm Laboratories, Inc.CompletedHealthyUnited States
-
Indiana UniversityTerminatedExercise-induced Arterial HypoxemiaUnited States